AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 61 min read

Alector, Inc. Stock 12‑Month Price Target Raised to $3.3, Implies 66% Upside

Alector, Inc.'s average stock price target increased from $3.1 to $3.3, with a range of $1 to $6, according to 5 analysts. This implies a 66% upside from the Oct. 5 closing price. The consensus rating remains 'Hold' among 7 analysts.

Original reporting
tradingview.com
Published Oct 6, 2026, 7:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 7:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Alector, Inc. Stock 12‑Month Price Target Raised to $3.3, Implies 66% Upside — source image
Source · tradingview.com
Decision brief

The 30-second read

Low
01

Why it matters

Analyst consensus remains Hold, but target increase suggests modest upside.

02

Market read

Small but notable for traders tracking micro‑cap biotech price‑target moves.

03

What to watch

Potential dilution from upcoming financing not reflected in target.

Relevance 5/10Novelty 4/10Timing: today

Background

Alector is a clinical-stage biotech focused on neurodegeneration.

Market effects

Sector

Minimal; biotech sector may see slight uplift from analyst optimism.

Regional

None

Global

Low

Counterpoint

What could challenge this read

Target raise may be premature if upcoming trial data disappoints.

Key entities

  • Company
    Alector, Inc.

    Biotech firm receiving higher analyst price target.

Read at source← All news

Related articles

OCT 7
MedAI 8/10

Genentech pays Alector $100m for Parkinson drug

Genentech paid Alector $100m upfront for global rights to AL050, a Parkinson's drug. Alector may receive up to $1.17b in milestones. AL050 targets GCase deficiency, a factor in Parkinson's. The deal extends Alector's cash runway to 2029, supporting other Alzheimer's and Parkinson's programs.

bioxconomy.com2 min
OCT 6
HighAI 9/10

Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion

Roche will pay up to $1.27 billion to license Alector's experimental Parkinson's therapy, AL050. The deal includes a $100 million upfront payment and potential milestone payments. Alector's shares surged 72% in premarket trading. Roche's Genentech unit will handle development and commercialization, with Alector eligible for royalties.

ksl.com2 min
OCT 5
$ALECHigh

Alector (ALEC) Shares Jump 22% on Genentech Licensing Deal for A

Alector Inc (ALEC) shares rose 22% after announcing a licensing deal with Genentech for its AL050 program. The deal includes a $100M upfront payment and potential milestone payments up to $1.17B. Alector's P/S ratio is 17.46, higher than historical and industry averages, reflecting growth expectations. The company's GF Score is 31/100, indicating weak fundamentals but some momentum.

gurufocus.com2 min